LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 32; p. S1318
Main Authors: Girard, N., Mazieres, J., Otto, J., Lena, H., Lepage, C., Egenod, T., Smith, D., Madelaine, J., Gérinière, L., El Hajbi, F., Ferru, A., Clément-Duchêne, C., Madroszyk, A., Desrame, J., Morin, F., Langlais, A., Michel, P., Louvet, C., Westeel, V., Walter, T.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.2119